worth a listen around the 3:18 mark a leading expert in CML calls ponatinib a "great advance" and expects that it will be used in a front-line setting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.